“It is a relevant investment of 12,000 million pesos of the pharmaceutical sector of Mexico, which is a high priority for the president, primarily because of its impact on the world, on the health of Mexicans and the forecast of always being ready for any pandemic or any circumstance,” he explained.
The 12,000 million pesos will be invested by Boehringer Ingelheim, Carnot Laboratories, Bayer and Astrazeneca.
Boehringer Ingelheim will invest 3.5 billion pesos to have a table of tablet production in Xochimilco, which will be the largest in the world, even greater than those that are available in Spain, China, Japan, Greece and Germany.
“From Xochimilco, to the south of Mexico City, we will supply the local market of anti hypertensive and antidiabetics, but we will also export to 40 countries on all continents in the world. This achievement is thanks to Mexican talent, as we expect direct employment of 1,800 collaborators, in addition to promoting around 15,000 indirect jobs,” said the director of Boehringer Ingelheim, Augusto Muench.
In the case of Carnot laboratories, the investment will be 3.5 billion pesos for a new plant, which, they advanced, generate 600 direct jobs with a high specialty and around 5,000 indirect.
